通心络胶囊联合沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能分级、血浆脑钠肽水平的影响  

Effects of Tongxinluo Capsule combined with sacubitril valsartan sodium tablets on cardiac function grading and plasma brain natriuretic peptide level in patients with chronic heart failure

作　　者：赵玉琴 ZHAO Yu-qin(First Department of Cardiology,Shouguang People's Hospital,Weifang 262700,China)

机构地区：[1]寿光市人民医院心内一科,262700

出　　处：《中国现代药物应用》2025年第2期67-70,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 观察通心络胶囊联合沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能分级、血浆脑钠肽水平的影响。方法 选取60例慢性心力衰竭患者,根据治疗方案的不同将其分成对照组(30例)和观察组(30例)。对照组实施沙库巴曲缬沙坦钠片进行治疗,观察组实施通心络胶囊联合沙库巴曲缬沙坦钠片进行治疗。比较两组治疗前后心功能分级、心功能指标[左心室舒张末期内径(LVEDd)、左心室后壁厚度(LVPWT)、每搏输出量(SV)]、血流动力学指标(收缩压、舒张压、心率)、血浆脑钠肽水平、生存状况。结果 治疗后,两组心功能分级均优于治疗前,且观察组优于对照组(P<0.05)。治疗后,两组LVEDd、LVPWT均比治疗前更小,SV均比治疗前更高,且观察组LVEDd(64.12±2.57)mm、LVPWT(10.42±0.96)mm均比对照组的(66.63±2.25)、(12.61±1.24)mm更小,SV(69.37±5.57)ml比对照组的(65.80±5.49)ml更高(P<0.05)。治疗后,两组收缩压、舒张压、心率均比治疗前更低,且观察组收缩压(126.79±7.87)mm Hg(1 mm Hg=0.133 kPa)、舒张压(79.34±5.10)mm Hg、心率(72.67±6.95)次/min均比对照组的(134.00±6.32)mm Hg、(87.84±6.65)mm Hg、(81.53±5.21)次/min更低(P<0.05)。治疗后,两组血浆脑钠肽水平均比治疗前更低,且观察组血浆脑钠肽(278.69±85.73)pg/ml比对照组的(371.04±92.61)pg/ml更低(P<0.05)。治疗后,两组症状频率、躯体局限、社交局限、生活质量评分均比治疗前更高,且观察组症状频率、躯体局限、社交局限、生活质量评分比对照组更高(P<0.05)。结论 通心络胶囊联合沙库巴曲缬沙坦钠片能够调节慢性心力衰竭患者血浆脑钠肽水平,改善心功能分级及心功能指标,对其生存状况有着重大意义。Objective To observe the effects of Tongxinluo Capsule combined with sacubitril valsartan sodium tablets on cardiac function grading and plasma brain natriuretic peptide level in patients with chronic heart failure.Methods 60 patients with chronic heart failure were selected and divided into control group(30 cases) and observation group(30 cases) according to different treatment regimens.The control group was treated with sacubitril valsartan sodium tablets,and the observation group was treated with Tongxinluo Capsule combined with sacubitril valsartan sodium tablets.Both groups were compared in terms of cardiac function grading,cardiac function index[ left ventricular end-diastolic diameter(LVEDd),left ventricular posterior wall thickness(LVPWT),stroke volume(SV)],hemodynamic index(systolic blood pressure,diastolic blood pressure,heart rate),plasma brain natriuretic peptide level and survival status before and after treatment.Results After treatment,the cardiac function grading in both groups was better than that before treatment,and the observation group was better than the control group(P<0.05).After treatment,LVEDd and LVPWT were smaller and SV was higher in both groups compared with those before treatment;the observation group had LVEDd of(64.12±2.57) mm and LVPWT of(10.42±0.96) mm,which were smaller than(66.63±2.25) and(12.61±1.24) in the control group;the observation group had higher SV of(69.37±5.57) ml than(65.80±5.49) ml in the control group(P<0.05).After treatment,the systolic blood pressure,diastolic blood pressure and heart rate in both groups were lower than those before treatment;in the observation group,the systolic blood pressure was(126.79±7.87) mm Hg(1 mm Hg=0.133 kPa),the diastolic blood pressure was(79.34±5.10) mm Hg,and the heart rate was(72.67±6.95) beats/min,which were lower than(134.00±6.32) mm Hg,(87.84±6.65) mm Hg,and(81.53±5.21) beats/min in the control group(P<0.05).After treatment,the plasma brain natriuretic peptide level in both groups was lower than that before treatme

关 键 词：通心络胶囊 沙库巴曲缬沙坦钠片 慢性心力衰竭 心功能分级 血浆脑钠肽水平 

分 类 号：R541.6[医药卫生—心血管疾病]